Previous 10 | Next 10 |
Novan (NOVN) -18.6% premarket, on implementing, a one-for-ten reverse split of its issued and outstanding common stock today.Shares are expected to begin trading tomorrow on a split-adjusted basis when the market opens. In July, 2020, the company’s stockholders approved ...
IAC/InterActiveCorp (IAC) -31%.Novan (NOVN) -18% on announcing 1-for-10 reverse stock split.Petros Pharmaceuticals (PTPI) -18%.Achieve Life Sciences (ACHV) -15% on proposing stock offeringLordstown Motors (RIDE) -13% on Q1 earnings releaseCreative Realities (CREX...
DURHAM, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it has filed a Certificate of Amendment to the Restated Certificate of Incorporation of the Company to implement a one-for-ten reverse split...
Gainers: MultiPlan (MPLN) +17%, Trinity Biotech (TRIB) +15%, Acutus Medical (AFIB) +11%, Novan (NOVN) +8%, Salarius Pharmaceuticals (SLRX) +7%.Losers: Evoke Pharma (EVOK) -17%, Curis (CRIS) -16%, UroGen Pharma (URGN) -16%, Eargo (EAR...
4 Biotech Penny Stocks to Watch in May 2021 Throughout the last year, investors have been passionately pursuing biotech penny stocks. This was in the hope that vaccine-related innovation would drive these penny stocks up. Because of this, some biotech penny stocks saw massiv...
Novan (NOVN): Q1 GAAP EPS of -$0.06 misses by $0.01.Revenue of $0.82M (-32.2% Y/Y) misses by $0.14M.Press Release For further details see: Novan EPS misses by $0.01, misses on revenue
– Topline efficacy results for ongoing Phase 3 study evaluating SB206 as a treatment for molluscum on track for targeted readout before the end of Q2 2021 – – Preclinical program underway evaluating SB019 with berdazimer sodium as a potential intranasal ther...
– Topline data on track for readout before the end of Q2 2021 – – Currently no FDA-approved therapies for the treatment of molluscum – – Potential for NDA filing no later than Q3 2022 – DURHAM, N.C., May 03, 2021 (GLOBE NEW...
Novan, Inc. is a late-clinical-stage biotechnology company specializing in therapeutics based on nitric oxide's naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action. Novan has a pipeline of 6 NO-based therapeutics with 5 in the clinica...
Gainers: Takung Art (TKAT) +33%.Teradata (TDC) +29%.Renalytix AI (RNLX) +24%.Qualtrics International (XM) +24%.Galectin Therapeutics (GALT) +23%.Kaleido Biosciences (KLDO) +21%.CEL-SCI (CVM) +21%.Novan (NOVN) +20%.Nikola (NKLA) +17%.Equifax (EFX) +17%.Losers: Evolus (EOLS) ...
News, Short Squeeze, Breakout and More Instantly...
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward...
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6...
– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress ...